Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Mild to moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased survival. A small proportion of COPD patients may present with severe pulmonary hypertension, defined by a mean pulmonary artery pressure more than 35 mmHg (or more than 20 mmHg with a low cardiac index < 2 l/min/m2) with pulmonary vascular resistance more than 3 Wood units, measured by right heart catheterization (RHC). In these patients, pulmonary microvessels remodeling is the main cause of increase in pulmonary arterial pressure and is thought to result from the combined effects of hypoxia, inflammation, and loss of capillaries but the mechanisms are complex.
For these patients, no drugs have been approved for treatment and lung transplantation must be considered for the more severe patients who are eligible. A better characterization of these patients is needed.
We hypothesize that microvesicles generation and endothelial damage could be related to the severity of pulmonary hypertension due to COPD, assessed by pulmonary hemodynamic parameters. Circulating biomarkers of vascular damage and cell activation will be measured in blood samples from 80 COPD patients who have hemodynamic assessment by RHC. To go further, the origin of the particles will be characterized.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Catheterization | Procedure | Right heart catheterization, using the Swan-Ganz standard technique, to measure mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance |
| Measure | Description | Time Frame |
|---|---|---|
| Study the rate of circulating endothelial microparticles (EPPs) according to the severity of pulmonary hypertension associated with COPD. | Circulating biomarkers of vascular damage and cell activation will be measured in blood samples from COPD patients who have hemodynamic assessment by RHC. Samples will be withdrawn from occluded pulmonary artery and jugular vein during the exam. | - During the first hemodynamic assessment by RHC; - At 3 to 6 months, if hemodynamic control is required (RHC) |
| Measure | Description | Time Frame |
|---|---|---|
| Characterization of circulating microvesicles in pulmonary hypertension due to chronic obstructive pulmonary disease | Circulating markers of endothelium damage with circulating microvesicles will be dosed. | - During the first hemodynamic assessment by RHC; - At 3 to 6 months, if an hemodynamic control is required (RHC) |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Patients with chronic obstructive pulmonary disease, addressed to the competence center PulmoTension of the Strasbourg University hospital, France:
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marianne RIOU | Contact | +33 369551145 | marianne.riou@chru-strasbourg.fr |
| Name | Affiliation | Role |
|---|---|---|
| Marianne RIOU | Hôpitaux Universitaires de Strasbourg | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpitaux Universitaire de Strasbourg - Service Pneumologie - centre de compétence de l'hypertension artérielle pulmonaire - France | Strasbourg | 67091 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
During right-heart catheterization, blood samples are collected from the occluded pulmonary artery and the jugular vein.
Platelet-poor plasma (PPP) samples are obtained by double centrifugation.
| Characterization of circulating microvesicles in pulmonary hypertension due to chronic obstructive pulmonary disease |
Proinflammatory markers with circulating microvesicles will be dosed. |
| - During the first hemodynamic assessment by RHC; - At 3 to 6 months, if an hemodynamic control is required (RHC) |
| Characterization of circulating microvesicles in pulmonary hypertension due to chronic obstructive pulmonary disease | Cell stimulation estimated with circulating microvesicles will be dosed. | - During the first hemodynamic assessment by RHC; - At 3 to 6 months, if an hemodynamic control is required (RHC) |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002404 | Catheterization |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
| D008919 | Investigative Techniques |
Not provided
Not provided